Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasm Metastasis 25Leukemia, Myeloid, Acute 25Breast Neoplasms 19Prostatic Neoplasms 16Myelodysplastic Syndromes 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Multiple Myeloma 14Lung Neoplasms 13Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Triple Negative Breast Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Burkitt Lymphoma 11Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Myelomonocytic, Chronic 9Ovarian Neoplasms 8Melanoma 8Lymphoma, T-Cell 8Stomach Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, B-Cell 6Myeloproliferative Disorders 5Mouth Neoplasms 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Fallopian Tube Neoplasms 5

Interventions

canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Clonal Cytopenia of Undetermined Significance × Biopsy × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡